Alkermes plc. Outstanding Bonds Bonds
Note series still outstanding, nearest maturity first. Terms are from each offering's final pricing term sheet on SEC EDGAR; a reopening of the same CUSIP adds to its principal. Interest per payment = principal × coupon ÷ payments per year. Outstanding = principal issued minus each filed exchange, tender, redemption or conversion; it is (m) where the retired amount was not filed. Interest per payment uses the outstanding principal.
| Notes | Principal issued | Outstanding | Coupon | Trade date | Issue / settlement date | Maturity date | Interest payment dates | Interest per payment | Annual coupon interest | Optional redemption | Retired | Priced |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |